Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.910
-0.080 (-2.68%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $76.00K in the quarter ending March 31, 2026, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $618.00K, down -57.99% year-over-year. In the year 2025, Perspective Therapeutics had annual revenue of $884.00K, down -39.20%.
Revenue (ttm)
$618.00K
Revenue Growth
-57.99%
P/S Ratio
537.01
Revenue / Employee
$3,723
Employees
166
Market Cap
331.87M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 884.00K | -570.00K | -39.20% |
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Dec 31, 2022 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 207.32M |
| Delcath Systems | 90.44M |
| Standard BioTools | 86.26M |
| Sight Sciences | 79.55M |
| Electromed | 71.75M |
| 908 Devices | 57.80M |
| TriSalus Life Sciences | 44.88M |
| Senseonics Holdings | 40.71M |
CATX News
- 19 hours ago - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results - GlobeNewsWire
- 3 days ago - Perspective Therapeutics: EC grants OMP designation to (212Pb)VMT-alpha-NET - TheFly
- 3 days ago - Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs - GlobeNewsWire
- 14 days ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - GlobeNewsWire
- 21 days ago - Perspective Therapeutics management to meet virtually with BTIG - TheFly
- 23 days ago - Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics management to meet virtually with BTIG - TheFly
- 2 months ago - Perspective announces first patient dosed with (212Pb)VMT-alpha-NET - TheFly